The latest clinical outcomes from the largest and longest follow-up to the Diabetes Prevention Program (DPP) study will be presented Tuesday morning. The current phase of the Diabetes Prevention Program Outcomes Study (DPPOS) is scheduled to run through 2021 and is examining the long-term effects of metformin on cardiovascular disease and cancer outcomes, according to DPPOS Chair David M. Nathan, MD.
Latest DPPOS results on CVD, cancer incidence to be reported Tuesday
